Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease

ŞENTÜRK T., AYDINLAR A., YILMAZ Y., ORAL A. Y. , Ozdabakoglu O., Ulukaya E.

CORONARY ARTERY DISEASE, vol.20, no.8, pp.494-498, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 8
  • Publication Date: 2009
  • Doi Number: 10.1097/mca.0b013e328330d56a
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.494-498
  • Keywords: acute coronary syndrome, apoptosis, coronary artery disease, cytokeratin 18, ACUTE MYOCARDIAL-INFARCTION, CELL-DEATH, HEART-DISEASE, CYTOKERATIN-18, ACTIVATION, MARKERS
  • Bursa Uludag University Affiliated: Yes


Objectives Growing evidence has indicated the potential clinical usefulness of measuring different forms of cytokeratin 18 in patient sera (M30 antigen for apoptosis and M65 antigen for necrosis) for distinguishing different forms of cell death. Preliminary data have reported altered levels of cytokeratin 18 fragments in patients with acute coronary syndrome (ACS) and ischemic heart disease. In this study, serum levels of M30 and M65 were measured in 74 patients with ACS [including 17 cases with unstable angina and 57 patients with acute myocardial infarction (AMI)], 25 patients with stable angina, and 23 controls.